BRAUN
8.2.2024 15:01:31 CET | Business Wire | Press release
From its home of IPL at its world-class innovation facility in Kronberg, Germany, the pioneering German electronics brand, Braun, today introduces the Braun Skin i·expert - the only fully connected IPL system that learns, adapts, and provides personalised feedback in real time.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240131964639/en/
Braun Skin i·expert. Fully connected IPL system. (Photo: Business Wire)
The revolutionary new Skin i·expert is Braun’s fastest way to 1 year of smooth skin*, all in the comfort of your own home.
A smart system that automatically adapts the energy to your skin tone providing you with an active real-time personalised treatment guidance per body area – Braun puts the power in your hands, offering a more comfortable hair removal experience with the new Braun Skin i·expert.
All IPL devices within the Braun portfolio have been designed to offer fast, safe, almost painless hair removal and undergo countless R&D tests and scientific research to deliver the desired results you want and need.
Braun IPL devices are assessed by independent dermatologists and certified by Skin Health Alliance's high skin safety standards
- Smart Coverage Feedback and Smart Head Recognition enables you to achieve your best results by guiding you in real-time to avoid missing any treatment areas.
- The only one** with automatic flash power adaptation to your unique skin tones and a Skin Check to achieve your best results, in full safety. Followed by personalized tips on how you can improve your next session.
- No need to worry about missing an appointment thanks to its built in Personal Progress Tracker and Smart Calendar that enables you to stay on track by automatically adapting the sessions schedule by showing you how many treatments you still have left. Take control of your hair removal journey with ease and at a fraction of the cost of going to a salon.
Braun’s new IPL smart device is a step change to your hair removal routine, it gives the power to you to get long-lasting smooth skin safely, easily from the comfort of your home.
Ahmed Aboulenein, Global Vice President at Braun, said: “At Braun's Kronberg Innovation Center, our team are committed to designing durable and user-centered innovations that leverage cutting-edge technologies. Our aim is to delight consumers and address their Grooming everyday problems effectively. By gathering insights and data from consumers worldwide, Braun has identified a need for solutions that enable users to achieve safe and long-lasting smooth skin at home. This valuable information has informed our latest breakthrough IPL innovation. Our ultimate objective is to empower consumers, allowing them to achieve safe, long-lasting smooth skin comfortably from the convenience of their own homes. What sets the new Braun Skin i-expert apart is its seamless integration of smart technology, connecting the IPL device with a dedicated mobile app. This comprehensive system learns and adapts to the user's specific skin and hair needs, guiding them step by step through the entire treatment process. It provides real-time personalized feedback, making it remarkably user-friendly for both experienced IPL users and beginners.”
Dr. Christine Dierickx, MD, a leading cosmetic dermatologist and Director of Skinperium Laser and Cosmetic Dermatology Clinic in Luxembourg, said: “Hair removal is one of the top three reasons why patients visit a dermatologist. Many consumers opt also for salons as they believe at-home devices are complicated and do not deliver the desired results. The Braun Skin i·expert is a unique device that has been developed after years of research. It features an intuitive smart system that makes hair removal extremely simple for consumers. The device learns use after use to provide a personalized experience tailored just to you. Additionally, the automatic flash power adapts to your unique skin tones to ensure you achieve the best results, in full safety. The new Braun Skin i·expert is set to revolutionize the way we remove hair at home.”
*Following the regimen. Individual results may vary.
**Shared technology with Cyden
***Further reading: Hattersley AM, Kiernan M, Goldberg D, Dierickx C, Sliney DH, Haedersdal M, et al. Assessment of adverse events for a home‐use intense pulsed light hair removal device using postmarketing surveillance. Lasers Surg Med. 2023;1–9. https://doi.org/10.1002/lsm.23650
Notes to editors
About Braun
Braun, a subsidiary of Procter & Gamble founded in Germany in 1921, develops and manufactures a wide variety of small domestic appliances that marry technical innovation, reliable quality and distinctive design. These range from electric shavers and beauty products to household appliances, watches and speakers. Braun products enjoy worldwide distribution. Please visit www.braun.com for the latest news and in-depth information about the Braun brand.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240131964639/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Shilpa Medicare and Gate2Brain Sign Strategic Equity Partnership to Advance First-in-Class Brain Cancer Therapy8.6.2026 12:00:00 CEST | Press release
Shilpa Biocare Pvt Ltd, a Subsidiary of Shilpa Medicare Limited (BSE/NSE: SHILPAMED) has entered a strategic equity partnership with Gate2Brain, S.L., a biotechnology company focused on CNS therapeutics. Shilpa becomes a strategic shareholder and CMC, manufacturing, and regulatory partner for G2B-002 — Gate2Brain's lead program targeting deadly pediatric brain cancers, DIPG and pGBM, both with Orphan Drug Designation from the US FDA and EMA. G2B-002 uses Gate2Brain's proprietary MiniAp4 peptide shuttle to deliver SN-38 across the blood-brain barrier, demonstrating up to 100-fold greater brain drug transport preclinically. First-in-human trials are anticipated by FY28. G2B-002 targets high-growth oncology markets — the glioblastoma market projected at USD 6.48B by 2035 (CAGR: 7.97%), pediatric brain tumors at USD 2.47B by 2031 (CAGR: 6.9%), and DIPG at USD 1.2B by 2035 (CAGR: 7.1%). Gate2Brain's MiniAp4 platform further extends potential across rare pediatric cancers and broader CNS cat
Haleon Invests in India to Deliver Better Everyday Health to Rural Communities8.6.2026 11:11:00 CEST | Press release
£175m for first Haleon manufacturing site in Madhya Pradesh, central IndiaFast-growing India key to Haleon reaching one billion more consumers by 2030India’s consumer health market to reach over £23bn by 20301Accelerated rural distribution to access 3 million outletsAffordable Sensodyne packs and investment to double ‘last-mile’ reach in rural areas Haleon, a consumer company that is solely focused on better everyday health, today announces plans to expand its business in India, one of its fastest-growing markets and key to Haleon delivering its strategy and ambitions to reach one billion more consumers by 2030. Haleon will invest approximately £175 million2 in building a new oral health manufacturing site in Madhya Pradesh, central India and accelerate distribution efforts in rural India to meet rising demand. The new site will also support supply for wider Asia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608753094/e
Diabetology’s Breakthrough Clinical Data From Oraglutide™ Oral GLP-18.6.2026 10:56:00 CEST | Press release
Oraglutide™ Once Weekly, Low Dose, Low side-effect, Oral GLP-1 Glucose and Insulin Response Over 6 days: Clinical Data Posted at World ADA Diabetes & Obesity Conference Diabetology Limited (Jersey) poster presentation (https://diabetology.co.uk/ada-poster) 1724-P at the ADA 86th Scientific Session, New Orleans, reporting first human data from Oraglutide™ — small capsule intestinally-released oral semaglutide, formulated using the proprietary Axcess™ delivery technology. KEY HIGHLIGHTS 6-day glucose control: A single 4 mg oral dose of Oraglutide™ produced a sustained fall in glucose. Measuring 14% at Day 6 (p=.046), the longest duration presented from a single oral GLP-1 dose in a human IVGTT study. 28% increase in insulin secretion: Relative to placebo, insulin percent AUC increased by 12% day 0, (p=0.02) & 28% Day 1 (p = 0.025). Novel intestinal depot effect: Blood levels of semaglutide were higher on Day 1 than dosing on Day 0, consistent with lipid associated depot effect in the int
Reply at VivaTech 2026: Making AI, Agents and Robotics Happen Across the Enterprise8.6.2026 10:00:00 CEST | Press release
Reply[EXM, STAR: REY] is taking part in VivaTech 2026, Europe's largest innovation and technology event, held from June 17 to 20 at Paris Expo Porte de Versailles. At the event, Reply will showcase its latest innovations around AI for software engineering, AI-powered experiences, data and AI, and industrial AI. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608667672/en/ At VivaTech 2026 Reply will showcase its latest innovations around AI for software engineering, AI-powered experiences, data and AI, and industrial AI. Industries are being reshaped by AI, autonomous agents, robotics and new digital experiences. From strategy to execution, Reply helps companies move beyond experimentation and innovative ideas into concrete business value. Visitors can meet Reply in Hall 7.1, booth 1G12, and explore how, through real use cases, scalable solutions and live demonstrations, the group makes innovation happen. This year, Reply'
Cardiolife Partners with Bhutan Ministry of Health to Strengthen Nationwide Cardiac Care8.6.2026 10:00:00 CEST | Press release
Cardiolife is proud to partner with the Ministry of Health of Bhutan to roll out its advanced AI-powered ECG diagnostics system nationwide. The collaboration will provide access to early ECG diagnosis and prevention, marking a major step forward in the country’s effort to strengthen heart health and preventive care. Bhutan has a population of just over 700,000 people and heart failure and other cardiac conditionsare among the leading causes of death. Following constructive meetings in Thimphu, His Excellency, the Health Minister, officially endorsed the national rollout of Cardiolife’s solution and expressed appreciation for Cardiolife’s commitment to advancing cardiac care through the provision of free software and ECG equipment in Bhutan. “We are grateful to the Cardiolife team for their commitment to improving heart health in Bhutan. With cardiovascular diseases on the rise, this collaboration marks an important milestone in our journey to strengthen early detection and prevention a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
